Journal of International Psychiatry

【Abstract】 Objective: To investigate the clinical efficacy of paliperidone sustained-release tablets in the treatment of schizophrenia and the effect of serum IL-1β and MBP in patients. METHODS: Forty-eight patients with schizophrenia were enrolled in this study. From 2016.1 to 2017.6, 50 patients with schizophrenia were selected as observation group and 50 healthy subjects were selected as control group. Blood samples were taken from both subjects IL-1β and MBP were measured before and after treatment. Serum IL-1β and MBP concentrations were measured before and after treatment. The efficacy of the observation group was evaluated by negative and positive symptom scale (PANSS). Compared with the two groups, IL-1β, MBP concentration difference. Results: The negative symptoms, positive symptoms, psychopathological symptoms and PANSS scores of the observation group were 16.8 ± 4.2, 9.3 ± 2.1, 25.9 ± 3.0,55.7 ± 9.6, 10.2 ± 3.0 and 4.1 ± 0.9 respectively after treatment, 18.4 ± 2.8 and 32.7 ± 5.6, respectively. After treatment, the treatment group was significantly lower than the control group. The observation group was cured in 32 cases, markedly effective in 14 cases, effective in 2 cases, ineffective in 0 cases, the total effective rate was 100.0% (P <0.05). The levels of serum IL-1β and MBP in the observation group were significantly lower than those in the control group (P <0.05). Conclusion: The levels of IL-1β and MBP in patients with schizophrenia were significantly higher than those in patients with schizophrenia, and the effect of parylotide sustained-release tablets on the treatment of schizophrenia was accurate and the serum levels of IL-1β and MBP were decreased.

【Key words】 schizophrenia; paliperidone sustained-release tablets; interleukin 1β; myelin basic protein